Alan T N Tita1, Jeff M Szychowski1, Kim Boggess1, George Saade1, Sherri Longo1, Erin Clark1, Sean Esplin1, Kirsten Cleary1, Ron Wapner1, Kellett Letson1, Michelle Owens1, Adi Abramovici1, Namasivayam Ambalavanan1, Gary Cutter1, William Andrews1. 1. From the Departments of Obstetrics and Gynecology (A.T.N.T., J.M.S., W.A.), Biostatistics (J.M.S., G.C.), and Pediatrics (N.A.), University of Alabama at Birmingham, Birmingham; the Departments of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, Chapel Hill (K.B.), and Mission Hospital, Asheville (K.L.) - both in North Carolina; the University of Texas Medical Branch, Galveston (G.S.), and the University of Texas Health Sciences Center, Houston (A.A.); Ochsner Health System, New Orleans (S.L.); the University of Utah (E.C., S.E.) and Intermountain Health Care (E.C., S.E.), Salt Lake City; Columbia University, New York (K.C., R.W.); and the University of Mississippi, Jackson (M.O.).
Abstract
BACKGROUND: The addition of azithromycin to standard regimens for antibiotic prophylaxis before cesarean delivery may further reduce the rate of postoperative infection. We evaluated the benefits and safety of azithromycin-based extended-spectrum prophylaxis in women undergoing nonelective cesarean section. METHODS: In this trial conducted at 14 centers in the United States, we studied 2013 women who had a singleton pregnancy with a gestation of 24 weeks or more and who were undergoing cesarean delivery during labor or after membrane rupture. We randomly assigned 1019 to receive 500 mg of intravenous azithromycin and 994 to receive placebo. All the women were also scheduled to receive standard antibiotic prophylaxis. The primary outcome was a composite of endometritis, wound infection, or other infection occurring within 6 weeks. RESULTS: The primary outcome occurred in 62 women (6.1%) who received azithromycin and in 119 (12.0%) who received placebo (relative risk, 0.51; 95% confidence interval [CI], 0.38 to 0.68; P<0.001). There were significant differences between the azithromycin group and the placebo group in rates of endometritis (3.8% vs. 6.1%, P=0.02), wound infection (2.4% vs. 6.6%, P<0.001), and serious maternal adverse events (1.5% vs. 2.9%, P=0.03). There was no significant between-group difference in a secondary neonatal composite outcome that included neonatal death and serious neonatal complications (14.3% vs. 13.6%, P=0.63). CONCLUSIONS: Among women undergoing nonelective cesarean delivery who were all receiving standard antibiotic prophylaxis, extended-spectrum prophylaxis with adjunctiveazithromycin was more effective than placebo in reducing the risk of postoperative infection. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development; C/SOAP ClinicalTrials.gov number, NCT01235546 .).
RCT Entities:
BACKGROUND: The addition of azithromycin to standard regimens for antibiotic prophylaxis before cesarean delivery may further reduce the rate of postoperative infection. We evaluated the benefits and safety of azithromycin-based extended-spectrum prophylaxis in women undergoing nonelective cesarean section. METHODS: In this trial conducted at 14 centers in the United States, we studied 2013 women who had a singleton pregnancy with a gestation of 24 weeks or more and who were undergoing cesarean delivery during labor or after membrane rupture. We randomly assigned 1019 to receive 500 mg of intravenous azithromycin and 994 to receive placebo. All the women were also scheduled to receive standard antibiotic prophylaxis. The primary outcome was a composite of endometritis, wound infection, or other infection occurring within 6 weeks. RESULTS: The primary outcome occurred in 62 women (6.1%) who received azithromycin and in 119 (12.0%) who received placebo (relative risk, 0.51; 95% confidence interval [CI], 0.38 to 0.68; P<0.001). There were significant differences between the azithromycin group and the placebo group in rates of endometritis (3.8% vs. 6.1%, P=0.02), wound infection (2.4% vs. 6.6%, P<0.001), and serious maternal adverse events (1.5% vs. 2.9%, P=0.03). There was no significant between-group difference in a secondary neonatal composite outcome that included neonatal death and serious neonatal complications (14.3% vs. 13.6%, P=0.63). CONCLUSIONS: Among women undergoing nonelective cesarean delivery who were all receiving standard antibiotic prophylaxis, extended-spectrum prophylaxis with adjunctive azithromycin was more effective than placebo in reducing the risk of postoperative infection. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development; C/SOAP ClinicalTrials.gov number, NCT01235546 .).
Authors: Alan T N Tita; John C Hauth; Anne Grimes; John Owen; Alan M Stamm; William W Andrews Journal: Obstet Gynecol Date: 2008-01 Impact factor: 7.661
Authors: Maged M Costantine; Mahbubur Rahman; Labib Ghulmiyah; Benjamin D Byers; Monica Longo; Tony Wen; Gary D V Hankins; George R Saade Journal: Am J Obstet Gynecol Date: 2008-09 Impact factor: 8.661
Authors: William W Andrews; John C Hauth; Suzanne P Cliver; Karen Savage; Robert L Goldenberg Journal: Obstet Gynecol Date: 2003-06 Impact factor: 7.661
Authors: Lorie M Harper; Meredith Kilgore; Jeff M Szychowski; William W Andrews; Alan T N Tita Journal: Obstet Gynecol Date: 2017-08 Impact factor: 7.661
Authors: Eliza C Miller; Marisa Gallo; Erin R Kulick; Alexander M Friedman; Mitchell S V Elkind; Amelia K Boehme Journal: Stroke Date: 2018-05 Impact factor: 7.914
Authors: Lorene A Temming; Nandini Raghuraman; Ebony B Carter; Molly J Stout; Roxane M Rampersad; George A Macones; Alison G Cahill; Methodius G Tuuli Journal: Am J Obstet Gynecol Date: 2017-06-08 Impact factor: 8.661
Authors: Kim A Boggess; Alan Tita; Victoria Jauk; George Saade; Sherri Longo; Erin A S Clark; Sean Esplin; Kristin Cleary; Ronald Wapner; Kelli Letson; Michelle Owens; Sean Blackwell; Carmen Beamon; Jeffrey M Szychowski; William Andrews Journal: Obstet Gynecol Date: 2017-03 Impact factor: 7.661
Authors: Amy M Valent; Chris DeArmond; Judy M Houston; Srinidhi Reddy; Heather R Masters; Alison Gold; Michael Boldt; Emily DeFranco; Arthur T Evans; Carri R Warshak Journal: JAMA Date: 2017-09-19 Impact factor: 56.272
Authors: Mauricio La Rosa; Victoria Jauk; George Saade; Kim Boggess; Sherri Longo; Erin A S Clark; Sean Esplin; Kirsten Cleary; Ronald Wapner; Kellett Letson; Michelle Y Owens; Sean Blackwell; Jeff M Szychowski; William W Andrews; Alan T Tita Journal: Obstet Gynecol Date: 2018-08 Impact factor: 7.661